Despite major microsurgical improvements the clinical outcome of peripheral nerve surgery is still regarded as suboptimal. Over the past decade several innovative techniques have been developed to extend the armamentarium of the nerve surgeon. This review evaluates the potential of gene therapy in the context of peripheral nerve repair. First the main challenges impeding peripheral nerve regeneration are presented. This is followed by a short introduction to gene therapy and an overview of its most important advantages over the classical delivery of therapeutic proteins. Next, this review focuses on the most promising viral vectors capable of targeting the peripheral nervous system and their first application in animal models. In addition, the challenges of translating these experimental results to the clinic, the limitations of current vectors and the further developments needed, are discussed. Finally, four strategies are presented on how gene therapy could help patients that have to undergo reconstructive nerve surgery in the future.
A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology. 1996, 46: 1244–9.
2.
AartsenWMvan CleefKWPellissierLP. GFAP-driven GFP expression in activated mouse Muller glial cells aligning retinal blood vessels following intravitreal injection of AAV2/6 vectors. PLoS One. 2010, 5: e12387–e12387.
3.
ArakiKShiotaniAWatabeK. Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury. Gene Ther. 2006, 13: 296–303.
4.
AyusoEMingozziFBoschF. Production, purification and characterization of adeno-associated vectors. Curr Gene Ther. 2010, 10: 423–36.
5.
BattistonBPapaliaITosPGeunaS. Chapter 1: Peripheral nerve repair and regeneration research: A historical note. Int Rev Neurobiol. 2009, 87: 1–7.
6.
BaumgartnerBJShineHD. Neuroprotection of spinal motoneurons following targeted transduction with an adenoviral vector carrying the gene for glial cell line-derived neurotrophic factor. Exp Neurol. 1998, 153: 102–12.
7.
BeardBCDickersonDBeebeK. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther. 2007, 15: 1356–65.
8.
BlankinshipMJGregorevicPAllenJM. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther. 2004, 10: 671–8.
9.
BlitsBCarlstedtTPRuitenbergMJ. Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brain-derived neurotrophic factor. Exp Neurol. 2004, 189: 303–16.
10.
CaoLLinEJCahillMC. Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat Med. 2009, 15: 447–54.
11.
CartierNHacein-Bey-AbinaSBartholomaeCC. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009, 326: 818–23.
12.
ChattopadhyayMWolfeDHuangS. In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol. 2002, 51: 19–27.
13.
ChengCZochodneDW. In vivo proliferation, migration and phenotypic changes of Schwann cells in the presence of myelinated fibers. Neuroscience. 2002, 115: 321–9.
14.
ChenuaudPLarcherTRabinowitzJE. Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol Ther. 2004, 9: 410–18.
15.
de BoerRKnightAMSpinnerRJ. In vitro and in vivo release of nerve growth factor from biodegradable poly-lactic-co-glycolic-acid microspheres. J Biomed Mater Res A. 2010, 95: 1067–73.
16.
de RuiterGCSpinnerRJMalessyMJ. Accuracy of motor axon regeneration across autograft, single-lumen, and multichannel poly(lactic-co-glycolic acid) nerve tubes. Neurosurgery. 2008, 63: 144–53.
17.
DoddSLHainBSenfSMJudgeAR. Hsp27 inhibits IKKbeta-induced NF-kappaB activity and skeletal muscle atrophy. FASEB J. 2009, 23: 3415–23.
18.
EggersRHendriksWTTannemaatMR. Neuroregenerative effects of lentiviral vector-mediated GDNF expression in reimplanted ventral roots. Mol Cell Neurosci. 2008, 39: 105–17.
19.
EggersRTannemaatMREhlertEMVerhaagenJ. A spatio-temporal analysis of motoneuron survival, axonal regeneration and neurotrophic factor expression after lumbar ventral root avulsion and implantation. Exp Neurol. 2010, 223: 207–20.
20.
EvansPJBainJRMackinnonSEMakinoAPHunterDA. Selective reinnervation: A comparison of recovery following microsuture and conduit nerve repair. Brain Res. 1991, 559: 315–21.
21.
FavreDBlouinVProvostN. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol. 2002, 76: 11605–11.
22.
FuSYGordonT. Contributing factors to poor functional recovery after delayed nerve repair: Prolonged axotomy. J Neurosci. 1995a, 15: 3876–85.
23.
FuSYGordonT. Contributing factors to poor functional recovery after delayed nerve repair: Prolonged denervation. J Neurosci. 1995b, 15: 3886–95.
24.
GloriosoJCFinkDJ. Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther. 2009, 17: 13–18.
25.
GoinsWFLeeKACavalcoliJD. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J Virol. 1999, 73: 519–32.
26.
GordonTSulaimanOALadakA. Chapter 24: Electrical stimulation for improving nerve regeneration: Where do we stand?Int Rev Neurobiol. 2009, 87: 433–44.
27.
GossenMBujardH. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992, 89: 5547–51.
28.
GossenMFreundliebSBenderG. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995, 268: 1766–9.
29.
GuHYChaiHZhangJY. Survival, regeneration and functional recovery of motoneurons after delayed reimplantation of avulsed spinal root in adult rat. Exp Neurol. 2005, 192: 89–99.
HaastertKLipokaticEFischerMTimmerMGrotheC. Differentially promoted peripheral nerve regeneration by grafted Schwann cells over-expressing different FGF-2 isoforms. Neurobiol Dis. 2006, 21: 138–53.
32.
Hacein-Bey-AbinaSvonKCSchmidtM. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003, 302: 415–19.
33.
HargrovePWKepesSHanawaH. Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther. 2008, 16: 525–33.
34.
HendriksWTJEggersRCarlstedtTP. Lentiviral vector-mediated reporter gene expression in avulsed spinal ventral root is short-term, but is prolonged using an immune ‘stealth’ transgene. Restor Neurol Neurosci. 2007, 25: 585–99.
35.
HokeABrushartT. Introduction to special issue: Challenges and opportunities for regeneration in the peripheral nervous system. Exp Neurol. 2010, 223: 1–4.
36.
HokeAGordonTZochodneDWSulaimanOAR. A decline in glial cell-line-derived neurotrophic factor expression is associated with impaired regeneration after long-term Schwann cell denervation. Exp Neurol. 2002, 173: 77–85.
37.
HokeARedettRHameedH. Schwann cells express motor and sensory phenotypes that regulate axon regeneration. J Neurosci. 2006, 26: 9646–55.
38.
HomsJArizaLPagesG. Schwann cell targeting via intrasciatic injection of AAV8 as gene therapy strategy for peripheral nerve regeneration. Gene Ther. 2011, 18: 622–30.
39.
HuXCaiJYangJSmithGM. Sensory axon targeting is increased by NGF gene therapy within the lesioned adult femoral nerve. Exp Neurol. 2010, 223: 153–65.
40.
Ijkema-PaassenJMeekMFGramsbergenA. Reinnervation of muscles after transection of the sciatic nerve in adult rats. Muscle Nerve. 2002, 25: 891–7.
41.
IsaacsJ. Treatment of acute peripheral nerve injuries: Current concepts. J Hand Surg Am. 2010, 35: 491–7.
42.
JessenKRMorganLStewartHJMirskyR. Three markers of adult non-myelin-forming Schwann cells, 217c(Ran-1), A5E3 and GFAP: Development and regulation by neuron-Schwann cell interactions. Development. 1990, 109: 91–103.
43.
KaplittMGFeiginATangC. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet. 2007, 369: 2097–105.
44.
KaplittMGLeonePSamulskiRJ. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 1994, 8: 148–54.
45.
KayMAGloriosoJCNaldiniL. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001, 7: 33–40.
46.
KempSWWalshSKZochodneDWMidhaR. A novel method for establishing daily in vivo concentration gradients of soluble nerve growth factor (NGF). J Neurosci Methods. 2007, 165: 83–8.
47.
KoliatsosVEPriceWLPardoCAPriceDL. Ventral root avulsion: An experimental model of death of adult motor neurons. J Comp Neurol. 1994, 342: 35–44.
48.
KouyoumdjianJA. Peripheral nerve injuries: A retrospective survey of 456 cases. Muscle Nerve. 2006, 34: 785–8.
49.
KumarMKellerBMakalouNSuttonRE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther. 2001, 12: 1893–905.
50.
KutnerRHZhangXYReiserJ. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc. 2009, 4: 495–505.
51.
KwonISchafferDV. Designer gene delivery vectors: Molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res. 2008, 25: 489–99.
52.
LambertPDAndersonKDSleemanMW. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA. 2001, 98: 4652–7.
53.
Latta-MahieuMRollandMCailletC. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther. 2002, 13: 1611–20.
54.
LavdasAAPapastefanakiFThomaidouDMatsasR. Cell adhesion molecules in gene and cell therapy approaches for nervous system repair. Curr Gene Ther. 2011, 11: 90–100.
55.
LundbergCBjorklundTCarlssonT. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther. 2008, 8: 461–73.
56.
McDonaldDChengCChenYZochodneD. Early events of peripheral nerve regeneration. Neuron Glia Biol. 2006, 2: 139–47.
57.
McPhailLTFernandesKJChanCCVanderluitJLTetzlaffW. Axonal reinjury reveals the survival and re-expression of regeneration-associated genes in chronically axotomized adult mouse motoneurons. Exp Neurol. 2004, 188: 331–40.
58.
MadisonRDArchibaldSJLacinRKrarupC. Factors contributing to preferential motor reinnervation in the primate peripheral nervous system. J Neurosci. 1999, 19: 11007–16.
MalessyMJPondaagWvan DijkJG. Electromyography, nerve action potential, and compound motor action potentials in obstetric brachial plexus lesions: Validation in the absence of a ‘gold standard’. Neurosurgery. 2009, 65(4 Suppl): A153–A159.
61.
MarksWJJrOstremJLVerhagenL. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurol. 2008, 7: 400–8.
62.
MasonMREhlertEMEggersR. Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. Mol Ther. 2010, 18: 715–24.
63.
MasonMRTannemaatMRMalessyMJVerhaagenJ. Gene therapy for the peripheral nervous system: A strategy to repair the injured nerve?Curr Gene Ther. 2011, 11: 75–89.
64.
MidhaR. Nerve transfers for severe brachial plexus injuries: A review. Neurosurg Focus. 2004, 16: E5–E5.
65.
MillesiHGanglbergerJBergerA. Erfahrungen mit der Mikrochirurgie peripherer Nerven. Langenbeck's Archives of Surgery. 1966, 316: 723–723.
66.
MontiniECesanaDSchmidtM. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006, 24: 687–96.
67.
MoradzadehABorschelGHLucianoJP. The impact of motor and sensory nerve architecture on nerve regeneration. Exp Neurol. 2008, 212: 370–6.
68.
NakajimaHUchidaKKobayashiS. Rescue of rat anterior horn neurons after spinal cord injury by retrograde transfection of adenovirus vector carrying brain-derived neurotrophic factor gene. J Neurotrauma. 2007, 24: 703–12.
69.
NaldiniLBlomerUGallayP. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996, 272: 263–7.
70.
PanYAMisgeldTLichtmanJWSanesJR. Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J Neurosci. 2003, 23: 11479–88.
Pereira LopesFRLisboaBCFrattiniF. Enhancement of sciatic-nerve regeneration after VEGF gene therapy. Neuropathol Appl Neurobiol. 2011EPUB ahead of print.
73.
RaivichGBohatschekMDaCC. The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron. 2004, 43: 57–67.
74.
RochkindSGeunaSShainbergA. Chapter 25: Phototherapy in peripheral nerve injury: Effects on muscle preservation and nerve regeneration. Int Rev Neurobiol. 2009, 87: 445–64.
75.
SchmidtCELeachJB. Neural tissue engineering: strategies for repair and regeneration. Annu Rev Biomed Eng. 2003, 5: 293–347.
76.
ScholzTKrichevskyASumartoA. Peripheral nerve injuries: An international survey of current treatments and future perspectives. J Reconstr Microsurg. 2009, 25: 339–44.
77.
SenfSMDoddSLMcClungJMJudgeAR. Hsp70 overexpression inhibits NF-kappaB and Foxo3a transcriptional activities and prevents skeletal muscle atrophy. FASEB J. 2008, 22: 3836–45.
78.
ShuXQMendellLM. Neurotrophins and hyperalgesia. Proc Natl Acad Sci USA. 1999, 96: 7693–6.
79.
SnyderBRBoulisNMFedericiT. Viral vector-mediated gene transfer for CNS disease. Expert Opin Biol Ther. 2010, 10: 381–94.
80.
StiegerKBelbellaaBLe GuinerCMoullierPRollingF. In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev. 2009, 61: 527–41.
81.
SulaimanOAGordonT. Effects of short- and long-term Schwann cell denervation on peripheral nerve regeneration, myelination, and size. Glia. 2000, 32: 234–46.
82.
Sunderland. Nerve injuries and their repair: A critical appraisal. Melbourne: Churchill Livingstone, 1991.
83.
TannemaatMRBoerGJEggersRMalessyMJVerhaagenJ. From microsurgery to nanosurgery: How viral vectors may help repair the peripheral nerve. Prog Brain Res. 2009, 175: 173–86.
84.
TannemaatMRBoerGJVerhaagenJMalessyMJ. Genetic modification of human sural nerve segments by a lentiviral vector encoding nerve growth factor. Neurosurgery. 2007, 61: 1286–94.
85.
TannemaatMREggersRHendriksWT. Differential effects of lentiviral vector-mediated overexpression of nerve growth factor and glial cell line-derived neurotrophic factor on regenerating sensory and motor axons in the transected peripheral nerve. Eur J Neurosci. 2008a, 28: 1467–79.
86.
TannemaatMRVerhaagenJMalessyM. The application of viral vectors to enhance regeneration after peripheral nerve repair. Neurol Res. 2008b, 30: 1039–46.
87.
TaylorCABrazaDRiceJBDillinghamT. The incidence of peripheral nerve injury in extremity trauma. Am J Phys Med Rehabil. 2008, 87: 381–5.
88.
UchidaNSuttonREFrieraAM. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci USA. 1998, 95: 11939–44.
WallerA. Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog, and the observations of the alterations produced thereby in the structure of their primitive fibres. Phil Trans Roy Soc Lond B. 1850, 140: 423–9.
91.
WalshSMidhaR. Practical considerations concerning the use of stem cells for peripheral nerve repair. Neurosurg Focus. 2009, 26: E2–E2.
92.
WangJZhangPWangY. The observation of phenotypic changes of Schwann cells after rat sciatic nerve injury. Artif Cells Blood Substit Immobil Biotechnol. 2010, 38: 24–8.
93.
WatabeKOhashiTSakamotoT. Rescue of lesioned adult rat spinal motoneurons by adenoviral gene transfer of glial cell line-derived neurotrophic factor. J Neurosci Res. 2000, 60: 511–19.
94.
WeberRABreidenbachWCBrownREJabaleyMEMassDP. A randomized prospective study of polyglycolic acid conduits for digital nerve reconstruction in humans. Plast Reconstr Surg. 2000, 106: 1036–45.
95.
XuQGMidhaRMartinezJAGuoGFZochodneDW. Facilitated sprouting in a peripheral nerve injury. Neuroscience. 2008, 152: 877–87.
YoungCMillerENicklousDMHoffmanJR. Nerve growth factor and neurotrophin-3 affect functional recovery following peripheral nerve injury differently. Restor Neurol Neurosci. 2001, 18: 167–75.
98.
ZacchignaSGiaccaM. Chapter 20: Gene therapy perspectives for nerve repair. Int Rev Neurobiol. 2009, 87: 381–92.
99.
ZaldumbideAWeeningSCramerSJ. A potentially immunologically inert derivative of the reverse tetracycline-controlled transactivator. Biotechnol Lett. 2010, 32: 749–54.
100.
ZincarelliCSoltysSRengoGRabinowitzJE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008, 16: 1073–80.
101.
ZuoYLubischerJLKangH. Fluorescent proteins expressed in mouse transgenic lines mark subsets of glia, neurons, macrophages, and dendritic cells for vital examination. J Neurosci. 2004, 24: 10999–1009.
